Author: Guang Yang; Zihu Tan; Ling Zhou; Min Yang; Lang Peng; Jinjin Liu; Jingling Cai; Ru Yang; Junyan Han; Yafei Huang; Shaobin He
Title: Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension Document date: 2020_4_4
ID: mwttkclk_26
Snippet: Further comparison found that IL-2, IL-7, IL-10, IP-10, MCP1, MIP1A, and TNFα were higher in ICU patients than non-ICU patients. 19 Elevated concentration of IL-6 were also demonstrated in COVID-19 patients with severe and critical disease compared with those with mild and common illness. 30, 31 Based on these evidence, a multicenter, randomized controlled trial was recently registered on Chinese Clinical Trial Registry (ChiCTR2000029765) to eva.....
Document: Further comparison found that IL-2, IL-7, IL-10, IP-10, MCP1, MIP1A, and TNFα were higher in ICU patients than non-ICU patients. 19 Elevated concentration of IL-6 were also demonstrated in COVID-19 patients with severe and critical disease compared with those with mild and common illness. 30, 31 Based on these evidence, a multicenter, randomized controlled trial was recently registered on Chinese Clinical Trial Registry (ChiCTR2000029765) to evaluate the efficacy and safety of IL-6R blockade with tocilizumab in the treatment of COVID-19.
Search related documents:
Co phrase search for related documents- control trial and evidence base: 1, 2, 3, 4
- control trial and ICU patient: 1
- control trial and multicenter randomized control trial: 1, 2, 3, 4, 5, 6, 7, 8
- control trial and randomized control trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- control trial and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- critical severe disease and evidence base: 1, 2
- critical severe disease and ICU patient: 1, 2, 3
- critical severe disease and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9
- critical severe disease and treatment tocilizumab: 1, 2, 3, 4, 5, 6
- critical severe disease patient and ICU patient: 1
- elevated concentration and safety efficacy: 1, 2
- evidence base and ICU patient: 1, 2
- evidence base and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- ICU patient and non icu patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- ICU patient and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- ICU patient and treatment tocilizumab: 1
- multicenter randomized control trial and randomized control trial: 1, 2, 3, 4, 5, 6, 7, 8
- multicenter randomized control trial and safety efficacy: 1, 2, 3, 4
- randomized control trial and safety efficacy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date